PASITHEA THERAPEUTICS CORP (KTTA) Stock Price, Quote, News and Overview
NASDAQ:KTTA - Nasdaq - US70261F2020 - Common Stock - Currency: USD
KTTA Quote, Performance and Key Statistics
1.4
-0.12 (-7.89%)
The current stock price of KTTA is 1.4 USD. In the past month the price increased by 10.24%. In the past year, price decreased by -79.77%.
KTTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About KTTA
Company Profile
Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company is headquartered in Miami Beach, Florida and currently employs 4 full-time employees. The company went IPO on 2021-08-13. The firm is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
Company Info
PASITHEA THERAPEUTICS CORP
1111 Lincoln Road, Suite 500
Miami Beach FLORIDA US
CEO: Tiago Reis Marques
Employees: 8
Phone: 17025144174
PASITHEA THERAPEUTICS CORP / KTTA FAQ
What is the stock price of PASITHEA THERAPEUTICS CORP today?
The current stock price of KTTA is 1.4 USD. The price decreased by -7.89% in the last trading session.
What is the ticker symbol for PASITHEA THERAPEUTICS CORP stock?
The exchange symbol of PASITHEA THERAPEUTICS CORP is KTTA and it is listed on the Nasdaq exchange.
On which exchange is KTTA stock listed?
KTTA stock is listed on the Nasdaq exchange.
What is PASITHEA THERAPEUTICS CORP worth?
PASITHEA THERAPEUTICS CORP (KTTA) has a market capitalization of 3.79M USD. This makes KTTA a Nano Cap stock.
How many employees does PASITHEA THERAPEUTICS CORP have?
PASITHEA THERAPEUTICS CORP (KTTA) currently has 8 employees.
What are the support and resistance levels for PASITHEA THERAPEUTICS CORP (KTTA) stock?
PASITHEA THERAPEUTICS CORP (KTTA) has a support level at 1.14 and a resistance level at 1.64. Check the full technical report for a detailed analysis of KTTA support and resistance levels.
Should I buy PASITHEA THERAPEUTICS CORP (KTTA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KTTA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KTTA, evaluating the profitability, health, valuation and growth aspects
- PASITHEA THERAPEUTICS CORP (KTTA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PASITHEA THERAPEUTICS CORP (KTTA) Sales and EPS estimates to see what analysts future expectations are.
- PASITHEA THERAPEUTICS CORP (KTTA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PASITHEA THERAPEUTICS CORP (KTTA) Insider and Institutional Ownership to learn about the owners and their transactions.
- PASITHEA THERAPEUTICS CORP (KTTA) Stock Chart to make your own analysis
- PASITHEA THERAPEUTICS CORP (KTTA) Latest news and press-releases to stay up to date.
Does PASITHEA THERAPEUTICS CORP (KTTA) stock pay dividends?
KTTA does not pay a dividend.
When does PASITHEA THERAPEUTICS CORP (KTTA) report earnings?
PASITHEA THERAPEUTICS CORP (KTTA) will report earnings on 2025-05-12.
What is the Price/Earnings (PE) ratio of PASITHEA THERAPEUTICS CORP (KTTA)?
PASITHEA THERAPEUTICS CORP (KTTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.81).
What is the Short Interest ratio of PASITHEA THERAPEUTICS CORP (KTTA) stock?
The outstanding short interest for PASITHEA THERAPEUTICS CORP (KTTA) is 16.95% of its float. Check the ownership tab for more information on the KTTA short interest.
KTTA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to KTTA. When comparing the yearly performance of all stocks, KTTA is a bad performer in the overall market: 96.09% of all stocks are doing better.
KTTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KTTA. While KTTA has a great health rating, there are worries on its profitability.
KTTA Financial Highlights
Over the last trailing twelve months KTTA reported a non-GAAP Earnings per Share(EPS) of -12.81. The EPS increased by 2.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -86.55% | ||
| ROE | -94.06% | ||
| Debt/Equity | 0 |
KTTA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to KTTA. The Buy consensus is the average rating of analysts ratings from 7 analysts.